Show simple item record

dc.contributor.authorLe Pen, Claude
dc.contributor.authorLévy, Emile
dc.contributor.authorBonte, J.
dc.subjectCost of Medical careen
dc.subjectMedical economicsen
dc.subjectCost-benefit analysisen
dc.titleCost-effectiveness analysis of captopril treatment after myocardial infarctionen
dc.typeArticle accepté pour publication ou publié
dc.description.abstractenThe recently published "Survival and Ventricular Enlargement" (SAVE), prospective controlled trial over 4 years including over 2,000 patients, has shown that long-term treatment with captopril reduced cardiovascular mortality (- 19%) and morbidity in patients with post-infarction left ventricular dysfunction without signs of cardiac failure. Based on the trial data, the extra cost of treating the patients with captopril compared with the placebo branch is estimated at 9.3 million french francs. This expense is compensated by a reduction in the cost of hospitalisation for cardiac failure of 1.6 million francs and a reduction in the cost of further coronary events of 3.4 million francs. Above all, the extra cost is compensated by a gain of 47 deaths avoided, corresponding to about 493.5 years of life saved. The cost-effectiveness of captopril administration is therefore about 8.750 francs per year per life saved. The ratio is significantly less than that of other primary or secondary prevention therapeutic strategies. On this basis, we conclude that captopril therapy of high risk post-infarction patients is a solution that is not only medically effective but also economically sound.en
dc.relation.isversionofjnlnameArchives des maladies du coeur et des vaisseaux
dc.relation.isversionofjnlpublisherSociété Française de Cardiologieen
dc.subject.ddclabelEconomie socialeen

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record